For research use only. Not for therapeutic Use.
BJE6-106 (Cat No.:I018746) is a small-molecule inhibitor that targets Protein Kinase C (PKC), a family of enzymes involved in signal transduction and cellular processes. By inhibiting PKC, BJE6-106 disrupts downstream signaling pathways, resulting in altered cellular responses. This inhibition shows promising potential as an anti-cancer strategy, selectively targeting cancer cells reliant on PKC signaling for proliferation. BJE6-106 has demonstrated anti-tumor effects, including inhibition of growth and metastasis, in preclinical studies. Ongoing research and clinical trials aim to evaluate BJE6-106 as a therapeutic option for cancer treatment, focusing on cancers where PKC dysregulation plays a significant role.
| Catalog Number | I018746 |
| CAS Number | 1564249-38-2 |
| Molecular Formula | C₂₆H₂₃NO₂ |
| Purity | ≥95% |
| Target | PKC; Apoptosis |
| IUPAC Name | 6-(2-carbazol-9-ylethyl)-2,2-dimethylchromene-8-carbaldehyde |
| InChI | InChI=1S/C26H23NO2/c1-26(2)13-11-19-15-18(16-20(17-28)25(19)29-26)12-14-27-23-9-5-3-7-21(23)22-8-4-6-10-24(22)27/h3-11,13,15-17H,12,14H2,1-2H3 |
| InChIKey | QLDDENZBVHBRKN-UHFFFAOYSA-N |
| SMILES | CC1(C=CC2=C(O1)C(=CC(=C2)CCN3C4=CC=CC=C4C5=CC=CC=C53)C=O)C |
| Reference | [1]. Takashima A,et al. Protein kinase Cδ is a therapeutic target in malignant melanoma with NRAS mutation. ACS Chem Biol. 2014 Apr 18;9(4):1003-14. |
